These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 7167209)

  • 1. Phosphate treatment of recurrent calcium stone disease.
    Heyburn PJ; Robertson WG; Peacock M
    Nephron; 1982; 32(4):314-9. PubMed ID: 7167209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcium phosphate supersaturation regulates stone formation in genetic hypercalciuric stone-forming rats.
    Bushinsky DA; Parker WR; Asplin JR
    Kidney Int; 2000 Feb; 57(2):550-60. PubMed ID: 10652032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The most important metabolic risk factors in recurrent urinary stone formers.
    Parvin M; Shakhssalim N; Basiri A; Miladipour AH; Golestan B; Mohammadi Torbati P; Azadvari M; Eftekhari S
    Urol J; 2011; 8(2):99-106. PubMed ID: 21656467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orthophosphate and other phosphate compounds in relation to stone formation.
    Fleisch H
    Adv Exp Med Biol; 1978; 103():203-16. PubMed ID: 213950
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of factors involved in calcium stone formation.
    Abraham PA; Smith CL
    Miner Electrolyte Metab; 1987; 13(3):201-8. PubMed ID: 3627051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful sodium thiosulphate treatment for recurrent calcium urolithiasis.
    Yatzidis H
    Clin Nephrol; 1985 Feb; 23(2):63-7. PubMed ID: 3886226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urine saturation with calcium salts in normal subjects and idiopathic calcium stone-formers estimated by an improved computer model system.
    Marangella M; Daniele PG; Ronzani M; Sonego S; Linari F
    Urol Res; 1985; 13(4):189-93. PubMed ID: 4049606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is calcium oxalate nucleation in postprandial urine of males with idiopathic recurrent calcium urolithiasis related to calcium phosphate nucleation and the intensity of stone formation? Studies allowing insight into a possible role of urinary free citrate and protein.
    Schwille PO; Schmiedl A; Manoharan M
    Clin Chem Lab Med; 2004 Mar; 42(3):283-93. PubMed ID: 15080561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Examination of crystalluria in freshly voided urines of recurrent calcium stone formers and normal individuals using a new filter technique.
    Fan J; Chandhoke PS
    J Urol; 1999 May; 161(5):1685-8. PubMed ID: 10210440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-Term Tolvaptan Increases Water Intake and Effectively Decreases Urinary Calcium Oxalate, Calcium Phosphate and Uric Acid Supersaturations.
    Cheungpasitporn W; Erickson SB; Rule AD; Enders F; Lieske JC
    J Urol; 2016 May; 195(5):1476-1481. PubMed ID: 26598423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines.
    Skolarikos A; Straub M; Knoll T; Sarica K; Seitz C; Petřík A; Türk C
    Eur Urol; 2015 Apr; 67(4):750-63. PubMed ID: 25454613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Essential arterial hypertension and stone disease.
    Borghi L; Meschi T; Guerra A; Briganti A; Schianchi T; Allegri F; Novarini A
    Kidney Int; 1999 Jun; 55(6):2397-406. PubMed ID: 10354288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proportional reduction of urine supersaturation during nephrolithiasis treatment.
    Coe FL; Wise H; Parks JH; Asplin JR
    J Urol; 2001 Oct; 166(4):1247-51. PubMed ID: 11547051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between supersaturation and calcium oxalate crystallization in normals and idiopathic calcium oxalate stone formers.
    Borghi L; Guerra A; Meschi T; Briganti A; Schianchi T; Allegri F; Novarini A
    Kidney Int; 1999 Mar; 55(3):1041-50. PubMed ID: 10027942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Phosphate therapy of recurrent calcium calculus disease. Current status].
    Schneider HJ; Rugendorff EW
    Fortschr Med; 1985 Feb; 103(5):104-6. PubMed ID: 3972326
    [No Abstract]   [Full Text] [Related]  

  • 16. Divergence between stone composition and urine supersaturation: clinical and laboratory implications.
    Lingeman J; Kahnoski R; Mardis H; Goldfarb DS; Grasso M; Lacy S; Scheinman SJ; Asplin JR; Parks JH; Coe FL
    J Urol; 1999 Apr; 161(4):1077-81. PubMed ID: 10081841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thiazides reduce brushite, but not calcium oxalate, supersaturation, and stone formation in genetic hypercalciuric stone-forming rats.
    Bushinsky DA; Asplin JR
    J Am Soc Nephrol; 2005 Feb; 16(2):417-24. PubMed ID: 15647340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dietary control for out-patients in urinary stone clinic].
    Kato T; Yanagawa M; Hioki T; Sakurai M; Yamakawa K; Araki T; Yamamoto I; Arima K; Tochigi H; Kawamura J
    Hinyokika Kiyo; 1993 Jul; 39(7):593-8. PubMed ID: 8362676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group.
    Prezioso D; Strazzullo P; Lotti T; Bianchi G; Borghi L; Caione P; Carini M; Caudarella R; Ferraro M; Gambaro G; Gelosa M; Guttilla A; Illiano E; Martino M; Meschi T; Messa P; Miano R; Napodano G; Nouvenne A; Rendina D; Rocco F; Rosa M; Sanseverino R; Salerno A; Spatafora S; Tasca A; Ticinesi A; Travaglini F; Trinchieri A; Vespasiani G; Zattoni F;
    Arch Ital Urol Androl; 2015 Jul; 87(2):105-20. PubMed ID: 26150027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemical factors governing the state of saturation towards brushite and whewellite in urine of calcium stone formers.
    Ackermann D; Baumann JM
    Urol Res; 1987; 15(2):63-5. PubMed ID: 3590430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.